A 52-week multicenter retrospective real-world study on effectiveness and safety of dupilumab in children with atopic dermatitis aged from 6 to 11 years
Background: Dupilumab has been shown to be a safe and effective drug for the treatment of atopic dermatitis (AD) in children from 6 months to 11 years in randomized clinical trials. Aim: The aim of this real-life study was to determine the effectiveness in disease control and safety of dupilumab at W52 in moderate-to-severe AD children aged 6-11 years.Methods: All data were collected from 36 Italian dermatological or paediatric referral centres. Dupilumab was administered at label dosage with an induction dose of 300 mg on day 1 (D1), followed by 300 mg on D15 and 300 mg every 4 weeks (Q4W). Treatment effect was determined as overall disease severity, using EASI, P-NRS, S-NRS and c-DLQI at baseline, W16, W24, and W52. Ninety-six AD children diagnosed with moderate-to-severe AD and treated with dupilumab were enrolled.Results: Ninety-one (94.8%) patients completed the 52-week treatment period and were included in the study. A significant improvement in EASI score, P-NRS, S-NRS and c-DLQI was observed from baseline to weeks 16, 24 and 52.Conclusions: Our real-life data seem to confirm dupilumab effectiveness and safety in paediatric patients. Moreover, our experience highlighted that patients achieving clinical improvement at W16 preserved this condition over time.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:34 |
|---|---|
| Enthalten in: |
The Journal of dermatological treatment - 34(2023), 1 vom: 24. Dez., Seite 2246602 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
420K487FSG |
|---|
| Anmerkungen: |
Date Completed 16.08.2023 Date Revised 16.08.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1080/09546634.2023.2246602 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360802222 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360802222 | ||
| 003 | DE-627 | ||
| 005 | 20231226083806.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/09546634.2023.2246602 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1202.xml |
| 035 | |a (DE-627)NLM360802222 | ||
| 035 | |a (NLM)37580895 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Patruno, Cataldo |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A 52-week multicenter retrospective real-world study on effectiveness and safety of dupilumab in children with atopic dermatitis aged from 6 to 11 years |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.08.2023 | ||
| 500 | |a Date Revised 16.08.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Background: Dupilumab has been shown to be a safe and effective drug for the treatment of atopic dermatitis (AD) in children from 6 months to 11 years in randomized clinical trials. Aim: The aim of this real-life study was to determine the effectiveness in disease control and safety of dupilumab at W52 in moderate-to-severe AD children aged 6-11 years.Methods: All data were collected from 36 Italian dermatological or paediatric referral centres. Dupilumab was administered at label dosage with an induction dose of 300 mg on day 1 (D1), followed by 300 mg on D15 and 300 mg every 4 weeks (Q4W). Treatment effect was determined as overall disease severity, using EASI, P-NRS, S-NRS and c-DLQI at baseline, W16, W24, and W52. Ninety-six AD children diagnosed with moderate-to-severe AD and treated with dupilumab were enrolled.Results: Ninety-one (94.8%) patients completed the 52-week treatment period and were included in the study. A significant improvement in EASI score, P-NRS, S-NRS and c-DLQI was observed from baseline to weeks 16, 24 and 52.Conclusions: Our real-life data seem to confirm dupilumab effectiveness and safety in paediatric patients. Moreover, our experience highlighted that patients achieving clinical improvement at W16 preserved this condition over time | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Atopic dermatitis | |
| 650 | 4 | |a children | |
| 650 | 4 | |a dupilumab | |
| 650 | 4 | |a real-world data | |
| 650 | 7 | |a dupilumab |2 NLM | |
| 650 | 7 | |a 420K487FSG |2 NLM | |
| 700 | 1 | |a Fabbrocini, Gabriella |e verfasserin |4 aut | |
| 700 | 1 | |a Lauletta, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Boccaletti, Valeria |e verfasserin |4 aut | |
| 700 | 1 | |a Colonna, Cristiana |e verfasserin |4 aut | |
| 700 | 1 | |a Cavalli, Riccardo |e verfasserin |4 aut | |
| 700 | 1 | |a Neri, Iria |e verfasserin |4 aut | |
| 700 | 1 | |a Ortoncelli, Michela |e verfasserin |4 aut | |
| 700 | 1 | |a Schena, Donatella |e verfasserin |4 aut | |
| 700 | 1 | |a Stingeni, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Hansel, Katharina |e verfasserin |4 aut | |
| 700 | 1 | |a Piccolo, Vincenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Di Brizzi, Veronica |e verfasserin |4 aut | |
| 700 | 1 | |a Potenza, Concetta |e verfasserin |4 aut | |
| 700 | 1 | |a Tolino, Ersilia |e verfasserin |4 aut | |
| 700 | 1 | |a Bianchi, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Manti, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a De Pasquale, Rocco |e verfasserin |4 aut | |
| 700 | 1 | |a Di Lernia, Vito |e verfasserin |4 aut | |
| 700 | 1 | |a Caminiti, Lucia |e verfasserin |4 aut | |
| 700 | 1 | |a Galli, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Coppo, Paola |e verfasserin |4 aut | |
| 700 | 1 | |a Chiricozzi, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a De Simone, Clara |e verfasserin |4 aut | |
| 700 | 1 | |a Guerriero, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Amoruso, Fabrizio Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Provenzano, Eugenio |e verfasserin |4 aut | |
| 700 | 1 | |a Leonardi, Salvatore |e verfasserin |4 aut | |
| 700 | 1 | |a Licari, Amelia |e verfasserin |4 aut | |
| 700 | 1 | |a Marseglia, Gian Luigi |e verfasserin |4 aut | |
| 700 | 1 | |a Palermo, Antonino |e verfasserin |4 aut | |
| 700 | 1 | |a Di Pillo, Sabrina |e verfasserin |4 aut | |
| 700 | 1 | |a Russo, Daniele |e verfasserin |4 aut | |
| 700 | 1 | |a Moschese, Viviana |e verfasserin |4 aut | |
| 700 | 1 | |a Patella, Vincenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Peduto, Tiziana |e verfasserin |4 aut | |
| 700 | 1 | |a Ferreli, Caterina |e verfasserin |4 aut | |
| 700 | 1 | |a Zangari, Paola |e verfasserin |4 aut | |
| 700 | 1 | |a Veronese, Federica |e verfasserin |4 aut | |
| 700 | 1 | |a Berti, Samantha Federica |e verfasserin |4 aut | |
| 700 | 1 | |a Gruber, Michaela |e verfasserin |4 aut | |
| 700 | 1 | |a Pezzolo, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Termine, Stefania |e verfasserin |4 aut | |
| 700 | 1 | |a Satta, Rosanna |e verfasserin |4 aut | |
| 700 | 1 | |a Dragoni, Federica |e verfasserin |4 aut | |
| 700 | 1 | |a Esposito, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Fargnoli, Maria Concetta |e verfasserin |4 aut | |
| 700 | 1 | |a Chiodini, Paolo |e verfasserin |4 aut | |
| 700 | 1 | |a Vallone, Ylenia |e verfasserin |4 aut | |
| 700 | 1 | |a di Vico, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Picone, Vincenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Napolitano, Maddalena |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of dermatological treatment |d 1992 |g 34(2023), 1 vom: 24. Dez., Seite 2246602 |w (DE-627)NLM088851680 |x 1471-1753 |7 nnns |
| 773 | 1 | 8 | |g volume:34 |g year:2023 |g number:1 |g day:24 |g month:12 |g pages:2246602 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/09546634.2023.2246602 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 34 |j 2023 |e 1 |b 24 |c 12 |h 2246602 | ||